vorinostat has been researched along with Duncan Disease in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Siddiqi, T | 1 |
| Frankel, P | 1 |
| Beumer, JH | 1 |
| Kiesel, BF | 1 |
| Christner, S | 1 |
| Ruel, C | 1 |
| Song, JY | 1 |
| Chen, R | 1 |
| Kelly, KR | 1 |
| Ailawadhi, S | 1 |
| Kaesberg, P | 1 |
| Popplewell, L | 1 |
| Puverel, S | 1 |
| Piekarz, R | 1 |
| Forman, SJ | 1 |
| Newman, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies[NCT01567709] | Phase 1 | 34 participants (Actual) | Interventional | 2012-04-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for vorinostat and Duncan Disease
| Article | Year |
|---|---|
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
Topics: Aurora Kinase A; Azepines; Histone Deacetylase Inhibitors; Humans; Lymphoproliferative Disorders; Ne | 2020 |